Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.62 |
| ▸ | CDC25B | P30305 | 2/20 | 0.59 |
| ▸ | CDC25A | P30304 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5155352 | 0.93 | KDM4E (0.68) | AKR1C3CDC25BCDC25AHSD17B10KDM4E | |
| SCHEMBL4834676 | 0.91 | CDC25B (0.56) | AKR1C3CDC25BCDC25AHSD17B10KDM4E | |
| SCHEMBL1819626 | 0.84 | NR4A1 (0.62) | AKR1C3CDC25BCDC25AHSD17B10KDM4E | |
| SCHEMBL10419449 | 0.84 | MEN1 (0.57) | AKR1C3CDC25BCDC25AHSD17B10KDM4E | |
| SCHEMBL333382 | 0.83 | CES2 (0.59) | AKR1C3KDM4EKEAP1ATMGAA | |
| SCHEMBL29765677 | 0.83 | CES2 (0.59) | AKR1C3KDM4EKEAP1ATMGAA | |
| SCHEMBL29367263 | 0.83 | CES2 (0.59) | AKR1C3KDM4EKEAP1ATMGAA | |
| SCHEMBL158348 | 0.83 | CES2 (0.59) | AKR1C3KDM4EKEAP1ATMGAA | |
| SCHEMBL27608795 | 0.83 | AKR1C3 (0.46) | AKR1C3CDC25BCDC25AHSD17B10KDM4E | |
| SCHEMBL30520290 | 0.82 | KEAP1 (0.65) | CDC25BCDC25AHSD17B10KDM4EKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1942456-A | Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors | SOSEI R & D LTD (GB) | 2007-04-04 | — | — | CN | disclosed |
| EP-1740558-A1 | BENZOXAZOCINES AND THEIR THERAPEUTIC USE AS MONOAMINE REUPTAKE INHIBITORS | Sosei R&D Ltd. (GB) | 2007-01-10 | — | — | EP | disclosed |
| US-20060019940-A1 | Novel benzoxazocines and their therapeutic use | SOSEI R&D LTD. (GB) | 2006-01-26 | — | — | US | disclosed |
| WO-2005103019-A1 | BENZOXAZOCINES AND THEIR THERAPEUTIC USE AS MONOAMINE REUPTAKE INHIBITORS | SOSEI R&D LTD. (GB) | 2005-11-03 | — | — | WO | disclosed |
| EP-0475527-B1 | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | SANOFI SA (FR) | 1998-02-25 | — | — | EP | disclosed |
| US-5624922-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0597540-B1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC (US) | 1996-06-05 | — | — | EP | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0597540-A1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| EP-0475527-A2 | Aryl-fused and hetaryl-fused-2, 4-diazepine and 2, 4-diazocine antiarrhythmic agents | STERLING DRUG INC. (US) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019940-A1 | Novel benzoxazocines and their therapeutic use | HTR4, OPRM1, GRM4 | AKR1C3 3345/4885CDC25B 1814/4885CDC25A 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.